The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12...

歐洲藥品管理局的人用藥品委員會已經通過了積極意見，推薦批准諾和諾德的Alhemo（Concizumab）作爲首個每日皮下預防性治療，適用於12歲及以上的人群。

Benzinga · 10/18 18:14

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

歐洲藥品管理局藥品人用委員會已經adopted積極意見，推薦批准諾和諾德Alhemo（Concizumab）作爲首個一天一次皮下預防性治療，適用於年滿12歲或以上患有出血性A或B並伴有抗體的人群。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。